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We report a case of a man who developed duodenal bleed-
ing caused by direct hepatocellular carcinoma (HCC) inva-
sion, which was successfully treated with endoscopic ethanol 
injection. A 57-year-old man with known HCC was admitted 
for melena and exertional dyspnea. He had been diagnosed 
with inoperable HCC a year ago. Urgent esophagogastroduo-
denoscopy (EGD) showed two widely eroded mucosal lesions 
with irregularly shaped luminal protruding hard mass on the 
duodenal bulb. Argon plasma coagulation and Epinephrine 
injection failed to control bleeding. We injected ethanol via 
endoscopy to control bleeding two times with 14 cc and 15 
cc separately without complication. Follow-up EGD catched 
a large ulcer with necrotic and sclerotic base but no bleed-
ing evidence was present. He was discharged and he did 
relatively well during the following periods. In conclusion, 
Endoscopic ethanol injection can be used as a signiﬁ  cantly 
effective and safe therapeutic tool in gastrointestinal tract 
bleeding caused by HCC invasion. (Gut Liver 2012;6:122-
125)
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INTRODUCTION
Gastrointestinal (GI) tract bleeding in patients with hepatocel-
lular carcinoma (HCC) is a common malady. The causes of GI 
tract bleeding in patients with HCC include varixes, peptic ul-
cers, gastropathy, Mallory-Weiss syndrome and tumor involve-
ment of the GI tract.
1 Bleeding from the GI tract by direct tumor 
invasion is very unusual and it has a very poor prognosis.
2-4 
Treatments that include surgery, transcatheter arterial chemo-
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embolization (TACE) and local injection often fail to stop the 
bleeding. Here we report on a case of a patient who developed 
duodenal bleeding that was caused by direct HCC invasion and 
this was successfully treated with endoscopic ethanol injection. 
CASE REPORT
A 57-year-old man with known HCC was admitted for me-
lena and exertional dyspnea that he’d experienced for the previ-
ous 3 days. He did not drink alcohol and the serologic markers 
for hepatitis B surface antigen and anti-hepatitis C virus were 
negative. He had been diagnosed with inoperable HCC one year 
previously and he had undergone TACE on a monthly basis. 
However, the HCC was not properly controlled and portal vein 
thrombosis developed (Fig. 1A and C). At the time of the diag-
nosis of HCC, esophagogastroduodenoscopy (EGD) showed only 
a duodenal ulcer scar on the bulb without varixes. On admis-
sion, his blood pressure was 99/54 mm Hg (normal, 120/80 mm 
Hg) and his pulse rate was 94/min (normal, 60 to 100/min). The 
physical examination showed paled conjunctiva and one palm-
breadth of hepatomegaly below the costal margin. The labora-
tory tests were as follows: hemoglobin, 5.5 g/dL (normal, 12.6 
to 17.4 g/dL), hematocrit, 16.8% (normal, 39% to 50%), white 
blood cell count, 5,150/μL (normal, 4,500 to 11,000/μL), platelet 
count, 104,000/μL (normal, 150,000 to 400,000/μL), serum pro-
tein, 6.1 g/dL (normal, 6.0 to 8.2 g/dL), albumin, 3.6 g/dL (normal, 
3.2 to 5.4 g/dL), aspartate transaminase, 116 IU/L (normal, 0 to 
50 IU/L), alanine transaminase, 133 IU/L (normal, 0 to 45 IU/
L), and total bilirubin, 0.39 mg/dL (normal, 0.0 to 1.6 mg/dL). 
Urgent EGD showed two widely eroded mucosal lesions with an 
hard, irregularly shaped mass on and protruding into the lumen 
of the duodenal bulb (Fig. 2A). Under the impression of direct Kim JN, et al: Endoscopic Ethanol Injection for Invasive Hepatocellular Carcinoma  123
Fig. 1. (A, B) A bulky hepatocellu-
lar carcinoma mass compresses the 
duodenum. (C, D) A tumor necrosis 
approximately 4 cm in diameter at 
the ethanol injection site (arrow).
Fig. 2. (A) A luminal protruding 
hepatocellular carcinoma mass on 
the duodenal bulb. (B) The regrowth 
of the mass with oozing on the duo-
denal bulb. (C) Endoscopic ethanol 
injection at the base of the mass. (D) 
Follow-up esophagogastroduodenos-
copy shows the necrosis of the mass 
on the duodenal bulb.124  Gut and Liver, Vol. 6, No. 1, January 2012
invasion of HCC into the duodenum, we performed snaring pol-
ypectomy for argon plasma coagulation (APC) and histological 
confirmation. The histologic findings showed duodenal inva-
sion of HCC (Fig. 3). His vital signs and hemoglobin level were 
improved after APC and blood transfusion. However, 15 days 
later, he again complained about melena and dyspnea. EGD 
revealed re-growth of the duodenal mass with oozing (Fig. 2B). 
We injected ethanol (95%) via endoscopy to control the cancer 
bleeding two times with doses of 14 and 15 cc, respectively (Fig. 
2C). Fourteen days later, follow-up EGD noticed a large ulcer 
with a necrotic and sclerotic base, but there was no evidence of 
bleeding (Fig. 2D). Follow-up abdominal computed tomography 
showed tumor necrosis in segment 4, which is where the etha-
nol had been injected (Fig. 1B and D). He was discharged and 
was doing relatively well during the following period. Sadly, the 
HCC progressed and he died of rebleeding and hepatic failure 3 
months later. 
DISCUSSION
HCC is one of the most common malignancies in the world 
and it is showing an increasing incidence in industrialized 
countries. Extrahepatic metastasis of HCC occurs in 30% to 
75% of the patients via three routes: direct invasion and the 
hematogenous and lymphogenous routes.
5 The most common 
metastatic site is the lung, followed by regional lymph nodes, 
bones, heart and adrenal glands.
6 GI tract involvement is rare, 
and this is seen in only 0.5% to 2% of the cases.
5,7 The most 
commonly involved site of the GI tract is the duodenum, fol-
lowed by the stomach, colon, and jejunum.
7,8 Patients with 
HCC and GI tract involvement were generally in an advanced 
stage of disease. A bulky tumor burden and persistent occult or 
frank GI tract bleeding are the main clinical manifestations of 
GI tract involvement of HCC.
5 Tumor invasion of the GI tract 
should be considered in the HCC patients with GI tract bleeding, 
and particularly in the cases without esophageal varices. Treat-
ments that include surgery, TACE and local injection have been 
carried out, but attempts to control this bleeding commonly 
fail. Therefore, these patients have a dismal prognosis. None of 
these patients have survived longer than 3 months except for 
two reported cases of HCC invading the duodenum; external 
beam radiotherapy was performed in one case
9 and TACE was 
performed in another
3 to control the bleeding. Surgery may 
offer significantly prolonged survival, yet most patients with 
HCC have liver cirrhosis and a poor liver function, and so these 
patients are not good candidates for resection. TACE may be an 
efficient treatment for GI tract bleeding. Traditionally, it is used 
for GI tract bleeding when endoscopic hemostasis is unsuccess-
ful. In this case, the patient had undergone TACE on a monthly 
basis, but his HCC was not properly controlled and portal vein 
thrombosis then developed. Therefore, TACE might not have 
controlled the bleeding. We controlled the bleeding via endo-
scopic ethanol injection. Percutaneous ethanol injection (PEI) 
was the first percutaneous treatment used in clinical practice 
and it is recommended as the standard ablation treatment for 
early stage nonsurgical HCC.
10 This technique involves a needle 
being introduced into the tumor and slow injection of absolute 
or 95% ethanol into the lesion. The ethanol induces tumor de-
struction by drawing water out of the tumor cells and denatur-
ing the structure of the cellular proteins, and so it can achieve a 
higher rate of complete tumor response for small HCCs.
11,12 The 
most common side effect of PEI is leakage of ethanol onto the 
surface of the liver and into the abdominal cavity, causing pain 
and fever. In the case of our patient, we injected ethanol into 
the tumor mass via endoscopy to control his GI tract bleeding 
from direct HCC invasion. The bleeding was successfully con-
trolled without side effects. Endoscopic ethanol injection is very 
simple to perform and it can be performed during EGD. 
As far as we know, this is the first case report that endoscopic 
ethanol injection successfully controlled GI tract bleeding from 
direct HCC invasion. In conclusion, endoscopic ethanol injection 
might be used as an effective and safe therapeutic tool for duo-
denal bleeding caused by HCC invasion. Yet further studies are 
necessary to clarify the effectiveness and safety of endoscopic 
ethanol injection in the setting of invasive HCC. 
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